999 Anti-Reflux Mucosectomy (ARMS) for Refractory Gerd and Initial Clinical Experience

Bapaye, Amol; Gangireddy, Siva Sankar Reddy; Mahadik, Mahesh; Pujari, Rajendra; Date, Suhas; Dubale, Nachiket; Bapaye, Jay

doi:10.1016/j.gie.2017.03.197

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From an initial 909 studies, 560 records were screened, and 36 full-length articles were reviewed. Ten studies were included in the final analysis that reported outcomes of ARMS 19 20 21 22 23 24 25 26 27 28 . The schematic diagram of study selection is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background and study aims Anti-reflux mucosectomy (ARMS) is an emerging endoscopic treatment for refractory gastroesophageal reflux disease (GERD). We conducted a systematic review and meta-analysis to evaluate the safety and efficacy ARMS in refractory GERD. Methods A comprehensive search of multiple databases (through March 2020) was performed to identify studies that reported outcomes of ARMS for refractory GERD. Outcomes assessed included technical success, clinical response, and adverse events (AEs). Clinical response was defined as discontinuation (complete) or reduction (partial) of proton pump inhibitors post-ARMS at follow up. Results A total of 307 patients (mean age 46.9 [8.1] years, 41.5 % females) were included from 10 studies. The technical success and clinical response rates were 97.7 % (95 % confidence interval [CI], 94.6–99.0) and 80.1 % (95 % CI, 61.6–91.0), respectively. The pooled rate of complete and partial clinical response was 65.3 % (95 % CI, 51.4–77.0) and 21.5 % (95 % CI, 14.2–31.2), respectively. The rate of AEs was 17.2 % (95 % CI, 13.1–22.2) with most common AE being dysphagia/esophageal stricture followed by bleeding with rates of 11.4 % and 5.0 %, respectively. GERD health-related quality of life (GERD-HRQL) (mean difference [MD] = 14.9, P < 0.001), GERD questionnaire (GERD-Q) (MD = 4.85, P < 0.001) and mean acid exposure time (MD = 2.39, P = 0.01) decreased significantly post-ARMS as compared to pre-procedure. There was no difference in terms of clinical response and AEs between ARMS and ARMS with banding on subgroup analysis. Conclusions ARMS is a safe and effective procedure for treatment of refractory GERD with high rates of clinical response, acceptable safety profile and significant improvement in GERD-related quality of life. Prospective studies are needed to validate our findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As shown in Table 1 , the DeMeester score was used in seven studies to assess the efficacy of ARMS. The DeMeester scores were significantly improved after the ARMS in all seven studies [ 11 , 15 – 17 , 22 – 24 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease

Zhu,

Shen

2024

Eur J Med Res

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is one of the most common diseases seen by gastroenterologists worldwide. A significant proportion of patients have a suboptimal response to acid inhibitors, especially proton pump inhibitors and potassium-competitive acid blockers. Due to concerns regarding the safety of long-term medication, many patients are unwilling to take lifelong medication. Endoscopic antireflux management offers a minimally invasive option for GERD patients. In recent decades, there have been several endoscopic antireflux therapies, including radiofrequency therapy, transoral fundoplication, and mucosal resection or mucosal ablation. Of these, antireflux mucosectomy (ARMS) is an effective and safe therapy for refractory GERD. This review provides an updated summary of antireflux mucosectomy.

show abstract

Radiofrequency Ablation (RFA) and Anti-Reflux MucoSectomy (ARMS) for Gastroesophageal Reflux Disease

Brimhall

Maydeo

Wagh

et al. 2019

Gastrointestinal Interventional Endoscopy

View full text Add to dashboard Cite

999 Anti-Reflux Mucosectomy (ARMS) for Refractory Gerd and Initial Clinical Experience

Cited by 6 publications

References 0 publications

Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease

Radiofrequency Ablation (RFA) and Anti-Reflux MucoSectomy (ARMS) for Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About